Article (Scientific journals)
Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis.
Belachew, Shibeshih; Phan-Ba, Rémy; Bartholome, Emmanuel et al.
2010In European Journal of Neurology, 18 (2), p. 240-245
Peer Reviewed verified by ORBi
 

Files


Full Text
Belachew EJN 2010.pdf
Publisher postprint (395.61 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] Background: Natalizumab (Tysabri) is a monoclonal antibody that was recently approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). Our primary objective was to analyse the efficacy of natalizumab on disability status and ambulation after switching patients with RRMS from other disease-modifying treatments (DMTs). Methods: A retrospective, observational study was carried out. All patients (n = 45) initiated natalizumab after experiencing at least 1 relapse in the previous year under interferon-beta (IFNB) or glatiramer acetate (GA) treatments. The patients also had at least 1 gadolinium-enhancing (Gd+) lesion on their baseline brain MRI. Expanded Disability Status Scale (EDSS) scores, and performance on the Timed 25-Foot Walk Test and on the Timed 100-Metre Walk Test were prospectively collected every 4 weeks during 44 weeks of natalizumab treatment. Brain MRI scans were performed after 20 and 44 weeks of treatment. Results: Sixty-two per cent of patients showed no clinical and no radiological signs of disease activity, and 29% showed a rapid and confirmed EDSS improvement over 44 weeks of natalizumab therapy. Patients with improvement on the EDSS showed similar levels of baseline EDSS and active T1 lesions, but had a significantly higher number of relapses, and 92% of them had experienced relapse-mediated sustained EDSS worsening in the previous year. A clinically meaningful improvement in ambulation speed was observed in approximately 30% of patients. Conclusions: These results indicate that natalizumab silences disease activity and rapidly improves disability status and walking performance, possibly through delayed relapse recovery in patients with RRMS who had shown a high level of disease activity under other DMTs.
Disciplines :
Neurology
Author, co-author :
Belachew, Shibeshih ;  Université de Liège - ULiège > Département des sciences cliniques > Neurologie
Phan-Ba, Rémy ;  Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Bartholome, Emmanuel;  C.H.U. Tivoli, La Louvière > Neurologie
Delvaux, Valérie ;  Centre Hospitalier Universitaire de Liège - CHU > Neurologie Sart Tilman
Hansen, Isabelle ;  Centre Hospitalier Universitaire de Liège - CHU > Neurologie Sart Tilman
Calay, Philippe ;  Centre Hospitalier Universitaire de Liège - CHU > Neurologie Sart Tilman
El Hafsi, Kaoutar;  Cliniques Universitaires de Bruxelles - Hôpital Erasme > Neurologie
Moonen, Gustave  ;  Centre Hospitalier Universitaire de Liège - CHU > Neurologie Sart Tilman
Tshibanda, Luaba ;  Centre Hospitalier Universitaire de Liège - CHU > Imagerie médicale
Vokaer, Mathieu;  Cliniques Universitaires de Bruxelles - Hôpital Erasme > Neurologie
Language :
English
Title :
Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis.
Publication date :
February 2010
Journal title :
European Journal of Neurology
ISSN :
1351-5101
eISSN :
1468-1331
Publisher :
Blackwell Science, Oxford, United Kingdom
Volume :
18
Issue :
2
Pages :
240-245.
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 06 November 2010

Statistics


Number of views
347 (37 by ULiège)
Number of downloads
342 (7 by ULiège)

Scopus citations®
 
67
Scopus citations®
without self-citations
63
OpenCitations
 
66

Bibliography


Similar publications



Contact ORBi